119 related articles for article (PubMed ID: 10752988)
21. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
Hehlmann R; Heimpel H; Hossfeld DK; Hasford J; Kolb HJ; Löffler H; Pralle H; Queisser W; Hochhaus A; Tichelli A; Fett W; Schmitz N; Reiter A; Griesshammer M; Pfeifer W; Bümler M; Kamp T; Tobler A; Eimermacher H; Kuse R; Berger U; Ansari H
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S21-4. PubMed ID: 8769695
[TBL] [Abstract][Full Text] [Related]
22. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
23. Persisting bone marrow aplasia following interferon-alpha combined with ara-C for chronic myelogenous leukemia.
Fiegl M; Chott A; Seewann HL; Lechner K; Gisslinger H
Leuk Lymphoma; 1999 Jun; 34(1-2):191-5. PubMed ID: 10350349
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
Hensley ML; Peterson B; Silver RT; Larson RA; Schiffer CA; Szatrowski TP
J Clin Oncol; 2000 Mar; 18(6):1301-8. PubMed ID: 10715301
[TBL] [Abstract][Full Text] [Related]
26. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
[TBL] [Abstract][Full Text] [Related]
27. [Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)].
Hehlmann R; Heimpel H; Heinze B; Georgii A; Kolb HJ; Hossfeld DK; von Wussow P; Hochhaus A; Griesshammer M; Diehl V
Onkologie; 1991 Feb; 14(1):66-73. PubMed ID: 2057176
[TBL] [Abstract][Full Text] [Related]
28. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
[TBL] [Abstract][Full Text] [Related]
29. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
30. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
[No Abstract] [Full Text] [Related]
31. Initial cytoreduction by mitoxantrone and cytarabine has no impact on the outcome of interferon-alfa-2b therapy in chronic myelogenous leukemia.
Nielsen H; Nielsen JL; Karle H
Eur J Haematol; 1992 Aug; 49(2):67-70. PubMed ID: 1397243
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
Lindauer M; Domkin D; Döhner H; Kolb HJ; Neubauer A; Huhn D; Kreiter H; Koch B; Huber C; Aulitzky W; Fischer T
Br J Haematol; 1999 Sep; 106(4):1013-9. PubMed ID: 10520005
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
34. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
35. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
[TBL] [Abstract][Full Text] [Related]
37. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Berger U; Hehlmann R
Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
39. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia.
Arthur CK; Ma DD
Acta Haematol; 1993; 89 Suppl 1():15-21. PubMed ID: 8475667
[TBL] [Abstract][Full Text] [Related]
40. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
